Liminatus Pharma (LIMN) Stock
Liminatus Pharma (LIMN) closed at $2.81 on Nov 19, 2026; its Tenet Score is 6 of 100 against 486 Healthcare peers.
Key stats
- Close
- $2.81
- Nov 19, 2026
- Market cap
- $5.4M
- share price × the latest quarter's diluted weighted-average share count (vendor)
- Dividend yield
- 0.00%
- reinvests all
- 52-week range
- 2.40 – 141.50
- low → high
- Tenet Score
- 6/100
- Weak · 486 Healthcare peers
Industry: Biological Products, Except Diagnostic Substances · see every company filed here →
Liminatus Pharma, Inc. scores 6/100. Weak. Quality is the soft spot versus 486 Healthcare peers. Insufficient inputs: Tenet 6 is built from 3 of 4 pillars, from 30% of its inputs. The pillars showing a dash had no data.
Tenet Score · vs sector
n=486Factor grades
Growth omitted — no data yet.
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Drawdown Context
- ✕ Reversal Evidence
- ✕ Quality Floor
- ~ Qualified Dip
Pays no dividend. Every dollar of profit is reinvested into the business.
13F flows & insider trades land here.
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocki…
Similar-sized companies in Biological Products, Except Diagnostic Substances
The 4 companies in this industry closest in market cap, as of Nov 13, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Cg Oncology Inc.CGON | 39 | $6.6B |
| Maze Therapeutics Inc.MAZE | 49 | $2.1B |
| Inhibrx Biosciences Inc.INBX | 30 | $1.2B |
| iShares Industrials Bond ETFENGN | 61 | $161.5M |
Common questions
What sector and industry is Liminatus Pharma in?
Liminatus Pharma is in the Healthcare sector and the Biological Products, Except Diagnostic Substances industry.
What is Liminatus Pharma's Tenet Score?
Liminatus Pharma's Tenet Score is 6 out of 100, ranked against 486 Healthcare peers as of Nov 20, 2026.



